LOGIN
Nadroparin or fondaparinux for thromboprophylaxis after ankle/foot fracture managed conservatively
December 2017
Nadroparin or fondaparinux for thromboprophylaxis after ankle/foot fracture managed conservatively
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial
Injury. 2017 Apr;48(4):936-940Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
467 patients managed with a below-knee plaster cast for a foot or ankle fracture were randomized to either subcutaneous nadroparin 2850IE daily, subcutaneous fondaparinux 2.5mg daily, or no thromboprophylaxis intervention (control). Patients were screened during follow-up for cases of deep vein thrombosis and pulmonary embolism. Results demonstrated significantly lower rates of deep vein thrombosi...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.